Trials / Not Yet Recruiting
Not Yet RecruitingNCT06064344
RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma
Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Non-Inferiority Randomized Controlled Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Intralesional Rituximab Injection |
| RADIATION | Involved Site Radiation Therapy | Involved Site Radiation Therapy |
Timeline
- Start date
- 2023-10-07
- Primary completion
- 2027-10-06
- Completion
- 2027-10-06
- First posted
- 2023-10-03
- Last updated
- 2023-10-03
Source: ClinicalTrials.gov record NCT06064344. Inclusion in this directory is not an endorsement.